Tumor Rejection by Modulation of Tumor Stromal Fibroblasts

Journal of Experimental Medicine

Volumn 198, Issue 10, 2003, Pages 1487-1493

  Schüler, Thomas ^a,c   Körnig, Sandra ^a   Blankenstein, Thomas ^a,b  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Angiogenesis; Bone marrow transplantation; Collagen; IL 4 receptor; Knockout mice

Indexed keywords

INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CELL TYPE; CHIMERA; CONTROLLED STUDY; CYTOKINE RELEASE; FIBROBLAST; HEMATOPOIETIC CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STROMA CELL; T LYMPHOCYTE; TARGET CELL; TUMOR REJECTION;

ANIMALS; BONE MARROW CELLS; CELL COMMUNICATION; CYTOTOXICITY, IMMUNOLOGIC; FIBROBLASTS; INTERLEUKIN-4; MICE; NEOPLASM TRANSPLANTATION; PLASMACYTOMA; RADIATION CHIMERA; RECEPTORS, INTERLEUKIN-4; STROMAL CELLS; T-LYMPHOCYTES;

EID: 0344585901     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20030849     Document Type: Article

References (45)

1. Tepper, R.I., P.K. Pattengale, and P. Leder. 1989. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell. 57:503-512.
2. Blankenstein, T., S. Cayeux, and Z. Qin. 1996. Genetic approaches to cancer immunotherapy. Rev. Physiol. Biochem. Pharmacol. 129:1-49.
3. Musiani, P., A. Modesti, M. Giovarelli, F. Cavallo, M.P. Colombo, P.L. Lollini, and G. Forni. 1997. Cytokines, tumour-cell death and immunogenicity: a question of choice. Immunol. Today. 18:32-36.
4. Noffz, G., Z. Qin, M. Kopf, and T. Blankenstein. 1998. Neutrophils but not eosinophils are involved in growth suppression of IL-4-secreting tumors. J. Immunol. 160:345-350.
5. Golumbek, P.T., A.J. Lazenby, H.I. Levitsky, L.M. Jaffee, H. Karasuyama, M. Baker, and D.M. Pardoll. 1991. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science. 254:713-716.
6. Hock, H., M. Dorsch, U. Kunzendorf, Z. Qin, T. Diamantstein, and T. Blankenstein. 1993. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma. Proc. Natl. Acad. Sci. USA. 90:2774-2778.
7. + lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4. J. Immunol. 153:5659-5673.
8. Tlsty, T.D., and P.W. Hein. 2001. Know thy neighbor: stromal cells can contribute oncogenic signals. Curr. Opin. Genet. Dev. 11:54-59.
9. Elenbaas, B., and R.A. Weinberg. 2001. Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp. Cell Res. 264:169-184.
10. Picard, O., Y. Polland, and M.F. Poupon. 1986. Fibroblast-dependent tumorigenicity of cells in nude mice: implication for implantation of metastases. Cancer Res. 46:3290-3294.
11. Horgan, K., D.L. Jones, and R.E. Mansel. 1987. Mitogenicity of human fibroblasts in vivo for human breast cancer cells. Br. J. Surg. 74:227-229.
12. Camps, J.L., S.M. Chang, T.C. Hsu, M.R. Freeman, S.J. Hong, H.E. Zhau, A.C. von Eschenbach, and L.W. Chung. 1990. Fibroblast-mediated acceleration of human epithelial tumor growth in vivo. Proc. Natl. Acad. Sci. USA. 87:75-79.
13. Noel, A., M.C. De Pauw-Gillet, G. Purnell, B. Nusgens, C.M. Lapiere, and J.M. Foidart. 1993. Enhancement of tumorigenicity of human breast adenocarcinoma ceus in nude mice by matrigel and fibroblasts. Br. J. Cancer. 68:909-915.
14. Olumi, A.F., G.D. Grossfeld, S.W. Hayward, P.R. Carroll, T.D. Tlsty, and G.R. Cunha. 1999. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 59:5002-5011.
15. Elenbaas, B., L. Spirio, F. Koerner, M.D. Fleming, D.B. Zimonjic, J.L. Donaher, N.C. Popescu, W.C. Hahn, and R.A. Weinberg. 2001. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev. 15:50-65.
16. Nelms, K., A.D. Keegan, J. Zamorano, J.J. Ryan, and W.E. Paul. 1999. The IL-4 receptor: signaling mechanisms and biologic functions. Annu. Rev. Immunol. 17:701-738.
17. Sempowski, G.D., M.P. Beckmann, S. Derdak, and R.P. Phipps. 1994. Subsets of murine lung fibroblasts express membrane-bound and soluble IL-4 receptors. Role of IL-4 in enhancing fibroblast proliferation and collagen synthesis. J. Immunol. 152:3606-3614.
18. Trautmann, A., G. Krohne, E.B. Brocker, and C.E. Klein. 1998. Human mast cells augment fibroblast proliferation by heterotypic cell-cell adhesion and action of IL-4. J. Immunol. 160:5053-5057.
19. Postlethwaite, A.E., M.A. Holness, H. Katai, and R. Raghow. 1992. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J. Clin. Invest. 90:1479-1485.
20. Makhluf, H.A., J. Stepniakowska, S. Hoffman, E. Smith, E.C. LeRoy, and M. Trojanowska. 1996. IL-4 upregulates tenascin synthesis in scleroderma and healthy skin fibroblasts. J. Invest. Dermatol. 107:856-859.
21. Ong, C., C. Wong, C.R. Roberts, H.S. Teh, and F.R. Jirik. 1998. Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma. Eur. J. Immunol. 28:2619-2629.
22. Kodera, T., T.L. McGaha, R. Phelps, W.E. Paul, and C.A. Bona. 2002. Disrupting the IL-4 gene rescues mice homozygous for the tight-skin mutation from embryonic death and diminishes TGF-beta production by fibroblasts. Proc. Natl. Acad. Sci. USA. 99:3800-3805.
23. + T cell IL-4 production is revealed in IL-4 receptor-deficient mice. Proc. Natl. Acad. Sci. USA. 94:10838-10843.
24. Van Vliet, E., M. Melis, J.M. Foidart, and W. Van Ewijk. 1986. Reticular fibroblasts in peripheral lymphoid organs identified by a monoclonal antibody. J. Histochem. Cytochem. 34:883-890.
25. Lusis, A.J. 2000. Atherosclerosis. Nature. 407:233-241.
26. Mumberg, D., P.A. Monach, S. Wanderling, M. Philip, A.Y. Toledano, R.D. Schreiber, and H. Schreiber. 1999. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc. Natl. Acad. Sci. USA. 96:8633-8638.
27. Nishimura, T., K. Iwakabe, M. Sekimoto, Y. Ohmi, T. Yahata, M. Nakui, T. Sato, S. Habu, H. Tashiro, M. Sato, et al. 1999. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J. Exp. Med. 190:617-627.
28. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity. 12:677-686.
29. Mattes, J., M. Hulett, W. Xie, S. Hogan, M.E. Rothenberg, P. Foster, and C. Parish. 2003. Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J. Exp. Med. 197:387-393.
30. + T cell subpopulations in established pulmonary metastases. J. Immunol. 162:6671-6680.
31. Becker, C., H. Pohla, B. Frankenberger, T. Schüler, M. Assenmacher, D.J. Schendel, and T. Blankenstein. 2001. Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay. Nat. Med. 7:1159-1162.
32. Dobrzanski, M.J., J.B. Reome, and R.W. Dutton. 2001. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection. J. Immunol. 167:424-434.
33. Schüler, T., and T. Blankenstein. 2003. Cutting edge: CD8(+) effector T cells reject tumors by direct antigen recognition but indirect action on host cells. J. Immunol. 170:4427-4431.
34. + T cells. Cancer Res. 63:4095-4100.
35. Di Carlo, E., A. Modesti, A. Coletti, M.P. Colombo, M. Giovarelli, G. Forni, M.G. Diodoro, and P. Musiano. 1998. Interaction between endothelial cells and the secreted cytokine drives the fate of an IL4- or IL5-transduced tumour. J. Pathol. 186:390-397.
36. Saleh, M., I.D. Davis, and A.F. Wilks. 1997. The paracrine role of tumour-derived mIL-4 on tumour-associated endothelium. Int. J. Cancer. 72:664-672.
37. Volpert, O.V., T. Fong, A.E. Koch, J.D. Peterson, C. Waltenbaugh, R.I. Tepper, and N.P. Bouck. 1998. Inhibition of angiogenesis by interleukin 4. J. Exp. Med. 188:1039-1046.
38. + effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor. J. Immunol. 164:916-925.
39. Wynn, T.A. 2003. IL-13 effector functions. Annu. Rev. Immunol. 21:425-456.
40. Han, C.I., G.R. Campbell, and J.H. Campbell. 2001. Circulating bone marrow cells can contribute to neointimal formation. J. Vasc. Res. 38:113-119.
41. Bucala, R., L.A. Spiegel, J. Chesney, M. Hogan, and A. Cerami. 1994. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol. Med. 1:71-81.
42. Chesney, J., C. Metz, A.B. Stavitsky, M. Bacher, and R. Bucala. 1998. Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes. J. Immunol. 160:419-425.
43. Abe, R., S.C. Donnelly, T. Peng, R. Bucala, and C.N. Metz. 2001. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J. Immunol. 166:7556-7562.
44. Salmon-Ehr, V., L. Ramont, G. Godeau, P. Birembaut, M. Guenounou, P. Bernard, and F.X. Maquart. 2000. Implication of interleukin-4 in wound healing. Lab. Invest. 80:1337-1343.
45. Dvorak, H.F. 1986. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315:1650-1659.